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AbsTrACT
background The epidemiological transition of non- communicable 
diseases replacing infectious diseases as the main contributors to 
disease burden has been well documented in global health literature. 
Less focus, however, has been given to the relationship between 
sociodemographic changes and injury. The aim of this study was to 
examine the association between disability- adjusted life years (DALYs) 
from injury for 195 countries and territories at different levels along the 
development spectrum between 1990 and 2017 based on the Global 
Burden of Disease (GBD) 2017 estimates.
Methods Injury mortality was estimated using the GBD mortality 
database, corrections for garbage coding and CODEm—the cause of 
death ensemble modelling tool. Morbidity estimation was based on 
surveys and inpatient and outpatient data sets for 30 cause- of- injury 
with 47 nature- of- injury categories each. The Socio- demographic Index 
(SDI) is a composite indicator that includes lagged income per capita, 
average educational attainment over age 15 years and total fertility 
rate.
results For many causes of injury, age- standardised DALY rates 
declined with increasing SDI, although road injury, interpersonal 
violence and self- harm did not follow this pattern. Particularly for 
self- harm opposing patterns were observed in regions with similar SDI 
levels. For road injuries, this effect was less pronounced.
Conclusions The overall global pattern is that of declining injury 
burden with increasing SDI. However, not all injuries follow this pattern, 
which suggests multiple underlying mechanisms influencing injury 
DALYs. There is a need for a detailed understanding of these patterns 
to help to inform national and global efforts to address injury- related 
health outcomes across the development spectrum.
InTrOduCTIOn
Injury is an important cause of morbidity and mortality in 
nations at any point of the development spectrum. Previous 
research has shown that in 2015, injuries accounted for 11% of 
the global burden of disease, expressed in disability- adjusted life 
years (DALYs), with an estimated 973 million people sustaining 
injuries warranting some type of healthcare and 4.7 million 
deaths.1 Globally, since 1990, focused injury burden research has 
documented a declining trend in the burden of injury of all the 
major causes of injury.2
The epidemiological transition of non- communicable diseases 
(NCDs) replacing infectious diseases as the main contributors 
to disease burden has been well- documented.1 3 4 However, less 
focus has been given to the relationship between sociodemo-
graphic changes and injury outcomes. Up till now, few studies 
have been performed that studied the relationship between 
sociodemographic changes and overall injury rates. There have 
been reports on the associations of gross domestic product and 
unemployment with suicides, homicides, road injury and unin-
tentional injuries.5–12 However, these studies focused on one 
specific cause of injury and on one type of injury outcome, 
mostly mortality. The findings of these studies indicated that the 
relationship between economic development and injury burden 
is not straightforward and mediated by many factors. A better 
understanding of this relationship may be achieved by investi-
gating all causes of injury as well as looking at both fatal and 
non- fatal injury outcome.
Insight into the epidemiological transitions with regard to 
injuries can be achieved by a systematic analysis of the relation-
ship between development and trends in mortality, incidence 
and burden of disease using a standardised approach. A system-
atic analysis may also reveal where health gains outpace or fall 
behind changes in development and allow for the identification 
of determinants and mediating factors of injury burden. This 
information allows identification determinants of injury burden. 
This information serves as a crucial input for guiding health 
system investments and priority- setting at the global, regional, 
national and subnational levels.
The Global Burden of Disease (GBD) 2015 study introduced 
a measure of development, the Socio- demographic Index (SDI). 
SDI combines information on income per capita, education and 
fertility. Comparisons between DALYs and SDI showed that 
age- standardised DALY rates for many communicable diseases 
declined profoundly over time, whereas improvements in SDI 
correlated strongly with the increasing importance of NCDs.4
This paper aims to provide an overview of injury mortality, 
incidence and DALYs from the GBD 2017 study, with detailed 
information on a range of causes of injuries; to examine the asso-
ciation between years of life lost (YLLs), YLDs and DALYs from 
injury and development, as measured by SDI, cause of injury, 
GBD region and over time; and to assess in which regions injury 
DALYs outpace or fall behind changes in development.
MeThOds
Gbd 2017 study
The GBD 2017 study methods and results have been described 
in extensive detail elsewhere, including description of the analyt-
ical estimation framework used to measure deaths, YLLs, YLDs 
and DALYs.4 13 14 A summary overview of the GBD study is 
provided in online supplementary appendix 1. The methodolog-
ical components specific to injuries estimation and SDI calcula-
tion are summarised below.
Injury incidence and death are defined as ICD-9 codes E800–
E999 and ICD-10 chapters V–Y, except for deaths and cases of 
drug overdoses and unintentional alcohol poisoning, which are 
classified under drug and alcohol use disorders. These external 
cause- of- injury codes or ‘E codes’ are designated as mutually 
exclusive and collectively exhaustive within the injuries estima-
tion process. In terms of the nature- of- injury codes (eg, the lower 
extremity amputation that can occur with a road injury), inju-
ries were categorised into 47 mutually exclusive and collectively 
exhaustive nature- of- injury categories using chapters S and T in 
International Classification of Disease (ICD) ICD-10 and codes 
800–999 in ICD-9 to quantify the various disabling outcomes 
of each cause of injury. Some injuries are trivial and unlikely 
to account for an important number of DALYs; hence, we only 
included injuries in our morbidity analysis that warranted some 
form of healthcare.
Injury mortality and YLLs
The overall approach to estimate causes of death is provided 
in related publications.13 15 16 A summary is as follows. We first 
mapped data sources using different versions of ICD or alter-
native classification systems to the GBD cause list. These data 
sources included vital registration, verbal autopsy, mortality 
surveillance, censuses, surveys, hospitals, police records and 
mortuary data. We then made adjustments for ill- defined causes 
of death such that they mapped to an underlying cause of death. 
Next, we conducted ensemble models using GBD cause of death 
ensemble modelling (CODEm) software to estimate cause- 
specific mortality by age, sex, country, year and cause. CODEm 
is described in more detail elsewhere but in summary explores 
a large variety of possible models to estimate trends in causes 
of death using an algorithm to select varying combinations of 
covariates that are run through several modelling classes. The 
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method then creates an ensemble of best- performing models that 
are determined by evaluating out- of- sample predictive validity. 
Deaths are then rescaled for each cause so that the sum equals 
the number of deaths from all causes to ensure internal consis-
tency. YLLs were calculated by multiplying deaths by the residual 
life expectancy at the age of death based on the GBD 2017 stan-
dard model life table.12
Injury incidence, prevalence and years lived with disability
Our method for estimating the incidence, prevalence and years 
lived with disability in non- fatal injury outcomes is provided 
in other GBD publications.2 14 A summary is as follows. We 
used DisMod- MR V.2.1 (a meta- regression tool for epidemio-
logical modelling) to model injury incidence using data from 
emergency department and hospital records and survey data 
to produce cause- of- injury incidence by location, year, age and 
sex. Across every injury cause model, we used national income 
per capita as a covariate on excess mortality, which forces a 
negative relationship between income and mortality to take 
into account higher case fatality in lower- resource settings. 
After modelling incidence of each cause of injury, we used 
a severity hierarchy to identify the nature- of- injury category 
that would lead to the most long- term burden when an indi-
vidual experiences multiple injuries. This hierarchy is based on 
pooled data sets of follow- up studies in which we translated 
each individual’s health status measure at 1 year after injury 
into a disability weight. This process is described in more detail 
in the GBD literature.12 14 17–22 Then, we generated matrices of 
the proportions of each cause of injury that are expected to 
lead to each nature of injury as determined in dual- coded (eg, 
both cause- of- injury and nature- of- injury coded) hospital and 
emergency department data sets and data from the Chinese 
National Injury Surveillance System.23 These data sets were 
used because the data were available in microdata format 
and they included dual- coded data in the format required for 
this specific part of the analysis. The resulting cause–nature 
matrices varied by injury warranting hospital admission versus 
injury warranting other healthcare, high- income/low- income 
countries, male/female and age group. In the next stage, we 
estimated short- term disability by cause and nature‐of‐injury 
category based on average duration for treated cases for each 
nature- of- injury category and for inpatient and outpatient 
injuries from the Dutch Injury Surveillance System.17 18 For 
19 of the 47 nature- of- injury categories (eg, foreign body in 
ear, poisoning and fracture in ear), we supplemented these 
estimates with expert- driven estimates of short- term duration 
for nature- of- injury categories when the data set had insuffi-
cient information. For untreated injuries, the average factor by 
which the duration of short- term injury outcomes is increased 
for a given nature- of- injury category when the injury goes 
untreated was estimated.
For longer- term injuries, we calculated the proportion of 
injuries that would result in disability lasting more than a year 
for each nature- of- injury category by admission status and age. 
This calculation was based on an assumption that disability from 
injury affects all cases in the short term with a proportion having 
persistent disability 1 year after the injury greater than the pre- 
injury health status. These probabilities of developing perma-
nent health loss were based on a pooled data set of seven large 
follow- up studies from China, the Netherlands and the USA 
that used patient- reported outcome measures to assess health 
status.17–22 24 25 We used the GBD healthcare access and quality 
(HAQ) index to estimate the ratio of treated to untreated injuries 
for each country–year grouping.26 The HAQ index is scaled from 
0 to 100 and is based on 32 causes of death, covering a range 
of health service areas, which should not occur if effective care 
is present. Finally, we used DisMod- MR V.2.1 to compute the 
long- term prevalence (ie, 1 year or more) for each cause–nature 
combination from incidence, which also incorporated increased 
mortality risk of certain nature of injuries, such as traumatic 
brain injury based on meta- analyses of studies providing stan-
dardised mortality ratios of these conditions. YLDs were calcu-
lated as prevalence of a health state multiplied by a disability 
weight. These estimates were then corrected for comorbidity 
with other non- fatal diseases using methods described elsewhere 
in the GBD study.13
socio-demographic Index
SDI is a composite indicator that includes income per capita, 
average educational attainment over age 15 years and total 
fertility rate under age 25 years. The SDI has a value that ranges 
from 0 to 1. 0 represents the lowest income per capita, lowest 
educational attainmentand highest fertility under age 25 years 
observed across all GBD geographies from 1980 to 2017. 1 
represents the highest income per capita, highest educational 
attainment and lowest fertility under 25 years observed across all 
GBD geographies from 1980 to 2017. The average relationship 
between YLLs, YLDs and YLDs divided by DALYs was calcu-
lated with SDI using Gaussian process regression modelling. We 
used these estimates of expected DALY rates that were predicted 
based on the full range of SDI to determine whether observed 
health patterns deviated from trends associated with changes 
along the development spectrum.
GATher compliance
This study complies with the GATHER (Guidelines for Accurate 
and Transparent Health Estimates Reporting) recommendations 
(online supplementary appendix 2).
resuLTs
Mortality, incidence and burden of injury, 2017
In 2017, worldwide 55.9 million (95% Uncertainty Interval (UI) 
55.4 to 56.5 million) people died. Of these deaths, 4.5 million 
(95% UI 4.3 to 4.6 million), 8.0% (95% UI 7.7% to 8.2%), were 
due to injuries. Major causes of injury deaths were road injury 
(27.7%), self- harm (17.7%), falls (15.5%) and interpersonal 
violence (9.0%).
There were 521 million (95% UI 493 to 548 million) cases 
of non- fatal injuries in 2017, representing an increase of 
167 million from the 354 million (95% UI 338 to 372 million) 
cases of non- fatal injuries in 1990. The global age- standardised 
injury death rate was 57.9 per 100 000 (95% UI 55.9 to 59.2), 
with highest death rates for road injury (15.8 deaths per 100 
000 (95% UI 15.2 to 16.3)), self- harm (10.0 deaths per 100 
000 (95% UI 9.4 to 10.3)) and falls (9.2 deaths per 100 000 
(95% UI 8.5 to 9.8)) (see online supplementary appendix table 
1). Injury death rates were over twice as high in men compared 
with women (80.9 per 100 000 (95% UI 77.7 to 83.0) and 
35.5 per 100 000 (95% UI 33.9 to 36.5), respectively). The 
global age- standardised injury incidence rate was 6762.6 per 
100 000 (95% UI 6412.0 to 7118.1)), with highest incidence 
rates for falls (2237.6 new cases per 100 000 (95% UI 1989.7 
to 2532.3)) and mechanical forces (943.6 new cases per 100 
000 (95% UI 808.7 to 1100.6)) (see online supplementary 
appendix table 1). Injury incidence rates were almost twice 
as high in men compared with women (7827.1 per 100 000 
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Figure 1 Age- standardised YLL and YLD rates for 17 cause- of- injury categories by level of Socio- demographic Index. YLL, years of life lost.
(95% UI 7435.3 to 8242.9) and 5654.5 per 100 000 (95% UI 
5351.3 to 5962.1), respectively).
Injuries contributed 10.1% (9.7%–10.5%) to the global 
burden of disease in 2017 (3267.0 DALYs per 100 000 
(95% UI 3058.2 to 3505.1)). YLLs were responsible for the 
majority of the injury DALYs (77%; 2548 YLLs per 100 000 
(95% UI 2462 to 2610)). The main contributors to injury 
DALYs were road injuries (871.1 DALYs per 100 000 (95% 
UI 827.9 to 917.3); 26.7%), falls (459.5 DALYs per 100 000 
(95% UI 387.1 to 547.5); 14.1%), self- harm (429.0 per 100 
000 (95% UI 401.6 to 443.5); 13.1%), interpersonal violence 
(334.3 DALYs per 100 000 (95% UI 304.7 to 360.5); 10.2%) 
and drowning (230.0 DALYs per 100 000 (95% UI 219.1 
to 241.2); 7.0%) (see online supplementary appendix table 
2). The injury burden was highest in Syria (16 341.1 DALYs 
per 100 000 (95% UI 15 892.7 to 16 858.4), Central African 
Republic (11 012.7 DALYs per 100 000 (95% UI 8807.9 to 
12 913.8)) and Lesotho (7951.3 DALYs per 100 000 (95% UI 
6424.8 to 9407.4)) and lowest in Maldives (1282.4 DALYs 
per 100 000 (95% UI 1138.1 to 1572.9)), Bermuda (1432.2 
DALYs per 100 000 (95% UI 1267.5 to 1606.7)) and Italy 
(1458.1 DALYs per 100 000 (95% UI 1237.2 to 1739.4)) 
(see online supplementary appendix table 3. SDI level for 
each country in 2017 is also provided).
Change over time
Between 1990 and 2017, the age- standardised injury DALY 
rates have declined from 4946 (95% UI 4655 to 5233) to 
3267 DALYs (95% UI 3058 to 3505) per 100 000, with 
largest absolute declines in drowning (from 635 (95% UI 
571 to 689) to 230 (95% UI 219 to 241) DALYs per 100 
000), road injuries (from 1259 (95% UI 1182 to 1330) to 
871 (95% UI 828 to 917) DALYs per 100 000), self- harm 
(from 687 (95% UI 621 to 723) to 429 (95% UI 402 to 
443) DALYs per 100 000), and fire, heat and hot substances 
(from 197 (95% UI 157 to 228) to 111 (95% UI 93 to 129) 
DALYs per 100 000). Between 1990 and 2017, the age- 
standardised rates of YLDs and YLLs from injuries declined 
by 7.8% and 38.8%, respectively, while incidence of injuries 
only declined by 0.9%.
burden of injury by sdI level
The contribution of cause- of- injury category DALY rates to 
the total injury DALY rates differed by year, age category, 
sex and SDI level. The largest disparity in DALY rate by SDI 
level was found in 0–6 days olds, ranging from a high of 
52 374 DALYs per 100 000 in the lowest SDI quintile to a 
low of 6109 DALYs per 100 000 in the highest SDI quintile. 
In men aged 15–49 years, conflict and terrorism stands out 
because of the high difference between highest and lowest 
DALY rates by level of SDI (countries with low SDI 496 
DALYs (95% UI 414 to 589) per 100 000; countries with 
high SDI 2 DALYs (95% UI 1 to 2) per 100 000).
YLL and YLD rates by SDI level
For many causes of injury, age- standardised YLL and YLD 
rates declined strikingly with increasing SDI, with propor-
tionally largest decreases in YLL rates for conflict and 
terrorism (low SDI level 163.4 YLLs per 100 000; high SDI 
level 0.06 YLLs per 100 000), animal contact (low SDI level 
140.0 YLLs per 100 000; high SDI level 2 YLLs per 100 000) 
and other unintentional injuries (low SDI level 7993 YLLs 
per 100 000; high SDI level 8.4 YLLs per 100 000). Figure 1 
shows the level of age- standardised YLLs and YLDs per 
100 000 against SDI (all regions, all years 1990–2017) by 
cause- of- injury. Largest decreases in YLD rates were seen for 
cause- of- injury categories conflict and terrorism, exposure 
to forces of nature and adverse effects of medical treatment. 
Exceptions were road injuries, self- harm and interpersonal 
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Figure 2 Co- evolution of all injury age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with comparison with 
the values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- demographic Index.
violence. The age- standardised YLL rate of road injuries was 
highest at the low- middle range SDI levels and lowest at 
higher SDI levels, whereas YLDs from road injuries increased 
at higher SDI. The age- standardised road injuries YLL rate 
increased from low SDI to low- middle SDI, but declined at 
higher levels of SDI. For falls, at higher levels of SDI, the 
composition of the disease burden shifted towards YLDs as 
the primary driver of DALYs. YLLs made up 63%, 61% and 
20% of DALYs from falls in low, middle and high SDI quin-
tiles, respectively. For road injuries, the proportion of YLLs 
dropped from 91% in countries with low SDI to 70% in 
countries with high SDI.
Expected based on SDI versus observed burden of injury by SDI level, 
1990–2017
Figure 2 shows the level of all injury age- standardised DALYs 
per 100 000 against SDI by GBD region from 1990 to 2017 
in comparison with expected values (black line) based on 
SDI alone. The icons appearing above the black line for 
DALYs represent worse than expected injury DALYs and the 
icons appearing below represent better than expected injury 
DALYs. As SDI generally increases over time, successive 
markers represent years between 1990 and 2017. Regions 
where injury DALY rates were notably greater than expected 
based on SDI included Central and Southern Sub- Saharan 
Africa, Oceania, Eastern Europe, Central Europe and high- 
income North America. Regions where injury DALY rates 
were notably lower than expected based on SDI included 
Eastern and Western Sub- Saharan Africa, South Asia, South-
east Asia and Western Europe.
Road injury
The expected road injury DALY rate by SDI shows that 
most regions decreased in terms of road injury DALYs as 
SDI increased over time (see figure 3). South Asia, East Asia, 
Southern Sub- Saharan Africa and Eastern Europe are excep-
tions to this pattern, showing an initial increase and then a 
decline. In GBD 2017, the regions with worse than expected 
road injury DALYs based on SDI included North Africa and 
Middle East, Southern and Central Sub- Saharan Africa, 
Eastern Europe and Oceania, while regions with markedly 
better than expected rates included Eastern Sub- Saharan 
Africa, South Asia and Southern Latin America.
Interpersonal violence
In 2017, in all regions except for Southern Sub- Saharan 
Africa, Central Latin America, Tropical Latin America, Eastern 
Europe, Caribbean, Oceania and high- income North America, 
the observed interpersonal violence DALY rates were better 
than expected based on SDI (see figure 4). Between 1990 and 
2017, in most regions with higher than expected DALYs, the 
gap between observed and expected interpersonal violence 
DALY rates decreased, except for Caribbean and Tropical Latin 
America, where the gap increased.
Self-harm
The patterns of observed and expected self- harm DALYs 
based on SDI by GBD regions between 1990 and 2017 
differed markedly from those of other injuries (see figure 5). 
In 1990, observed self- harm DALY rates in East Asia and 
Eastern Europe were worse than expected based on SDI 
but rapidly declined over time, with observed DALY rates 
lower than expected in 2017. Southern Sub- Saharan Africa 
had worse than expected DALY rates but the other regions 
of Sub- Saharan Africa had better than expected DALY rates. 
North Africa and Middle East, Western Europe, Southeast 
Asia, and Andean, Central and Tropical Latin America all 
had better than expected DALY rates.
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Figure 3 Co- evolution of road injury age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with comparison with 
the values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- demographic Index.
Figure 4 Co- evolution of interpersonal violence age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with 
comparison with the values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- 
demographic Index.
Drowning
Drowning DALY rates between 1990 and 2017 decreased 
in almost every GBD region regardless of their SDI value 
(figure 6), except for Oceania, Eastern Europe and Southern 
Sub- Saharan Africa. Eastern and Western Sub- Saharan Africa, 
North Africa and Middle East, Andean, Tropical, Central 
and Southern Latin America, Western Europe and Austral-
asia had better than expected DALY rates, while Oceania, 
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Figure 5 Co- evolution of self- harm age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with comparison with 
the values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- demographic Index.
Figure 6 Co- evolution of drowning age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with comparison with 
the values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- demographic Index.
East Asia and Eastern Europe had worse than expected 
DALY rates based on SDI.
Falls
The patterns in falls globally followed more dynamic trends 
across regions as SDI increased from 1990 to 2017 (see 
figure 7). The regions that performed worse than expected 
in terms of SDI were Central Europe, Eastern Europe, South 
Asia, Central Asia and Australasia. Among these, Central 
Asia and Central Europe decreased and then increased, 
while Eastern Europe increased and then decreased. South 
Asia decreased steadily, while Australasia increased steadily 
until recent years. Among regions that performed better than 
expected, Oceania had increasing rates as SDI increased, 
while high- income North America dropped precipitously 
and then started increasing as SDI increased.
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Figure 7 Co- evolution of falls age- standardised DALY rates with SDI for the world and 21 GBD regions for 1990–2017 with comparison with the 
values expected on the basis of SDI alone. DALY, disability- adjusted life year; GBD, Global Burden of Disease; SDI, Socio- demographic Index.
dIsCussIOn
For many causes of injury, age- standardised DALY rates declined 
strikingly with increasing SDI, although road injury, interper-
sonal violence and self- harm did not strictly follow this pattern. 
Particularly for self- harm opposing patterns were observed in 
regions with similar SDI levels, for example, the trends in high- 
income Asia Pacific were opposite the trends in Western Europe, 
despite their proximity in terms of SDI. For road injuries, this 
effect was less pronounced; for nearly all regions, road injury 
DALY rates declined after 2005.
In Southern Sub- Saharan Africa, injury DALYs were worse 
than expected based on SDI in the overall injuries category as 
well as many of the specific injuries. In this region, road injury 
and interpersonal violence were important causes explaining 
the gap between observed and expected levels of overall injury 
DALYs. Many underlying and intertwining determinants of the 
high levels of interpersonal violence have been cited, including 
income inequality and poverty, high unemployment, rapid social 
change, corruption and poor rule of law, gender inequality, 
family breakdown, access to firearms, and alcohol and drug 
abuse.27 Despite these difficulties, however, and the worse- than- 
expected performance relative to SDI, our findings show that 
the DALY rates in Southern Sub- Saharan Africa have decreased 
from 2000 to 2017. This trend tallies with a reported declining 
number of injury deaths among young adults in South Africa.28
Of regions with a middle- high SDI, Eastern Europe stands out, 
because for most causes of injury, DALYs were much worse than 
expected based on SDI, particularly in the period 1990–2005. A 
compelling explanation for this finding may be the dissolution of 
the former Soviet Union and the resulting social and economic 
consequences on health and mortality.29 However, others have 
argued that causes of the health crisis are more complex and 
may result from a combination of historical and contemporary 
forces, including lifestyle habits, such as alcohol use, economic 
impoverishment, widening social inequality and the breakdown 
of political institutions.30 31 It should be noted that our study did 
aim to assess determinants of the burden of injury and caution 
is needed in attempting to draw conclusions with regard to 
possible reasons for regional trends and differences.
Another notable finding from our study was that for falls, at 
the higher levels of SDI, the composition of the disease burden 
shifted towards YLDs, rather than YLLs, as a more prominent 
driver of DALYs compared with areas with lower SDI. The 
proportion of DALYs due to YLDs also increases with higher 
levels of SDI among other injuries. It is possible that this shift 
in distribution reflects decreased mortality among injuries when 
people in higher SDI locations have access to better healthcare 
services. The shift in road injuries, for example, could be brought 
about by injury- prevention measures reducing the severity of the 
injury sustained (eg, seat belts and helmets) or by improved access 
to better quality care after an injury (eg, trauma systems). It is 
also possible that in age- standardised analyses, the shift towards 
YLDs may be due to the ageing of the population of countries 
with high SDI with commensurate age- related increases in injury 
incidence. For example, the incidence of falls increases substan-
tially with age and most of the burden from falls in high- SDI 
countries occurs in the very old.32
Limitations
Our analysis has several limitations. First, as SDI and time are 
correlated, we may be over interpreting SDI as a driver of change 
as it could well be driven largely by other factors changing over 
time, not necessarily linked to SDI, such as climate change.
Second, limited data are available to quantify burden of 
injuries in the world. Major limitations of the cause- of- death 
data are low or absent coverage of vital registration or verbal 
autopsy data in many parts of the world, incompleteness of 
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What is already known on the subject
 ► Morbidity and mortality from injuries are known to be 
affected by socioeconomic development.
What this study adds
 ► This study provides more recent estimates of global morbidity 
and mortality from injuries with a greater level of detail than 
has previously been reported and with an updated method 
for measuring sociodemographic development.
 ► This study found that many injuries decreased in terms of 
morbidity and mortality as sociodemographic development 
increased over time, but also identified important exceptions 
to this trend.
 ► The study adds to the body of discussion on how economic 
development and sociodemographic changes should be 
considered in preventing future injury burden.
death certification systems and differences in the proportion 
of injury deaths classified in ill- defined codes.33–36 Few data 
were available for non- fatal injuries, and if data were avail-
able, injury was frequently recorded as a mix of cause and 
nature- of- injury codes and often a preponderance of nature- 
of- injury codes, while our analyses require attributing health 
outcomes to cause of injury. As a result, many non- fatal injury 
hospitals and emergency departments data sets could not be 
used. Furthermore, short- term duration of several nature- of- 
injury categories was based on expert- driven estimates because 
patient data was not available. Besides, gathering data on 
deaths and morbidity due to forces of nature (ie, disasters) 
and collective violence is complicated by the fact that their 
aftereffects may severely disrupt the infrastructure of vital and 
health registration systems.37 The statistical methods that we 
have used to assess mortality, incidence and prevalence can 
borrow strength over time and geography to ensure an esti-
mate for all causes and all countries. Nevertheless, estimates 
for populations and time periods with few or absent data are 
inherently less precise.
Non- fatal injuries are reported by both cause of injury and 
nature of injury. Since our model requires a one- to- one rela-
tionship between cause- of- injury and nature- of- injury cate-
gory, we developed a nature- of- injuries severity hierarchy 
that selects the injury that was likely to be responsible for 
the largest burden in a person with more than one injury. 
This means that we ignore the other injuries sustained by 
such individuals and this may have led to some underesti-
mation of the burden of non- fatal injury. We decided to use 
such a hierarchy after it proved difficult to use statistical 
methods on sparse data to parse estimates across co- occur-
ring injuries.
A second methodological limitation is the assessment of 
the probability of permanent health loss, one of the main 
drivers of non- fatal burden of disease. The probability of 
long- term injury was based on patient- reported outcome data 
from follow- up studies in just three countries. Also, long- 
term patient- reported outcome data may be influenced by 
response shift bias. Response shift is a change of outcome due 
to a change of the measurement perspective of the respon-
dent (‘internal measurement scale’), where the usual change 
is towards adaptation. In our study, response shift may have 
resulted in an underestimation of the severity of long- term 
consequences of injury and consequently, to an underestima-
tion of the non- fatal burden of injury.
Third, even though a strong correlation between SDI and 
injury DALYs, YLLs and YLDs was found, this cannot be inter-
preted as being causal in nature, because income per capita and 
education, two of the three components of SDI, were also used 
as covariates in all of the injury models except exposure to forces 
of nature and collective violence and legal intervention. In its 
original formulation, Murray et al suggested that SDI utility may 
be improved in the future through consideration of additional 
societal elements, such as inequality in each component.1
COnCLusIOns
The overall pattern is that of declining injury burden with 
increasing development. Not all injuries follow this pattern, 
suggesting that there are multiple underlying mechanisms influ-
encing injury outcomes. The detailed understanding of these 
patterns helps to inform countries how best to respond to 
changes in injury outcomes that occur with development and, in 
case of countries where health gains outpace development, may 
help to identify which prevention and/or healthcare measures 
have been taken in these countries.
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